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In a systematic study of O
6-alkylguanine DNA-alkyltransferase activity in the human colon and rectum, tumours were found to
occur in regions of low activity. These results are consistent with the hypothesis that O
6-alkylguanine DNA-alkyltransferase
levels and alkylating agent exposure may be important determinants of large bowel tumorigenesis.
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The DNA repair protein, O
6-alkylguanine DNA-alkyltransferase
(MGMT), provides protection against the carcinogenic, mutagenic
and cytotoxic effects of alkylating agents (O’Connor et al, 2000).
Thus, overexpression of MGMT in transgenic rodents protects
against methylating agent induced GC?AT transitions in the K-
ras oncogene and against colonic aberrant crypt formation (Zaidi
et al, 1995). We have found an association between low levels of
MGMT activity in adjacent normal mucosa and GC?AT transition
mutations, but not transversion mutations, in K-ras of colorectal
cancers (Jackson et al, 1997). Hypermethylation of the promoter
region of the O
6-alkylguanine DNA-alkyltransferase gene has simi-
larly been associated with GC?AT transition mutations in K-ras of
colorectal cancers (Esteller et al, 2000). Variations in MGMT activ-
ity may therefore determine susceptibility to mutagenic events due
to endogenous and exogenous methylating agents in the human
colon and rectum. MGMT activity in colorectal mucosa have been
shown to vary widely between individuals (e.g. Gerson et al, 1995;
Povey et al, 2000b) but the magnitude of intra-individual variation
within the colon is largely unknown. To date, human studies have
taken single biopsy samples to be representative of the normal
mucosa adjacent to colorectal cancers without validation. Varia-
tions, if any, in MGMT activity within the normal colon may
bias comparisons with tumour samples and between different
studies. The aim of this study was to examine for the ﬁrst time
in a systematic manner, the topographical pattern of MGMT activ-
ity of normal mucosa around colorectal cancers and to determine
the intra-individual variation in MGMT activity.
MATERIALS AND METHODS
Mucosal biopsy samples were obtained from seven patients with
tumours of the rectum, sigmoid colon and caecum. All but one
patient was male and their age ranged from 48 to 83 years.
Tumours were examined by a consultant histopathologist and the
histological classiﬁcation of the tumours is shown in Table 1: the
diameter of the tumours varied between 30 and 100 mm. Normal
mucosa samples were harvested upstream (proximal) and down-
stream (distal) to the freshly resected tumours at 1 cm intervals
for at least 5 cm, and at further intervals (in long specimens) until
both resection margins were reached. Tumour samples (up to two)
were taken along the same axis as the normal mucosa samples. All
samples were collected by a single experienced colorectal surgeon
(NP Lees). Care was taken to dissect the mucosa away from deep
layers during harvesting of normal mucosal samples and to avoid
areas of slough during harvesting of tumour samples. Samples were
snap frozen and then stored at 7808C until assayed. All surgical
specimens were examined by a consultant histopathologist to deter-
mine tumour stage and to exclude any background inﬂammatory
bowel disease in the normal mucosa.
A MGMT activity assay was performed on each sample as
previously described (Watson and Margison, 1999). Brieﬂy, the
tissue samples were thawed and 1 ml of ice cold buffer I (50 mM
Tris-HCl, pH 8.3, 1 mM EDTA, 3 mM dithiothreitol) containing
0.5 mM leupeptin (Sigma) was added. The tissues were homo-
genised and sonicated, phenylmethylsulphonylﬂuoride (Sigma;
50 mM in 100% ethanol) was added to a ﬁnal concentration of
0.5 mM, and the suspension centrifuged at 15000 r.p.m. for
10 min at 48C. The supernatant was removed and kept at 08C.
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Table 1 Patient characteristics and tumour site/size and histology
Max.
Patient Age/ Tumour diameter
no sex site (mm) Histology
1 47/M Rectum 45 Dukes B
2 73/M Rectum 52 Dukes B
3 83/F Caecum 100 Dukes C
4 61/M Rectum 35 Dukes C
5 64/M Rectum 40 Dukes A
6 76/M Sigmoid 30 Dukes C
7 48/M Rectum 30 Moderately dysplastic
tubulovillous adenoma
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cate, by measuring the ﬂuorescence of known dilutions with
Hoechst 33258 dye (1 mgm l
71) in TNE buffer (10 mM Tris base,
1m M EDTA, 0.2 mM NaCl, pH 7.4) read on a Biolite ﬂuorescent
microtitre plate reader. Calf thymus DNA standards (Pharmacia
biotech, ultrapure) of known DNA content were used for calibra-
tion.
The MGMT assay was performed three times for each extract,
using different extract volumes and the amount of [
3H]methyl
groups transferred from substrate calf thymus DNA (Sigma) to
protein, under conditions of excess substrate, was quantiﬁed by
liquid scintillation counting. MGMT activity was expressed as
fmole O
6-methylguanine removed per mg DNA. All samples from
the same patient were prepared and assayed simultaneously. The
coefﬁcient of variation within a triplicate assay was 7%; day to
day variation in a control sample was 11%.
Differences in MGMT activity between normal and tumour
samples were examined by ANOVA. The mean gradients of MGMT
activity proximal and distal to the tumours were calculated and a
one sample t-test, weighted according to the number of observa-
tions, used to test whether the mean gradients were signiﬁcantly
positive or negative. Gradients were assigned as negative if they
increased towards the tumour (irrespective of proximal or distal
direction).
RESULTS AND DISCUSSION
All tumour samples (n=13) and 100 out of 102 normal mucosal
samples contained detectable MGMT activity. MGMT activity
varied between 50.25 (limit of detection) and 37.9 fmole mg
71
DNA. Mean MGMT activities (+s.d.), proximal and distal to
the tumour, are shown in Table 2. For ﬁve of the six tumours
from the lower large bowel (sigmoid colon or rectum), MGMT
activity was signiﬁcantly higher in the tumour sample than in
the surrounding tissue (Table 2) but there was little evidence of
a ﬁeld effect (i.e. tumour tissue exerting an effect on ATase activ-
ity in normal mucosa which was proportional to tumour
proximity) within a limited region of the tumour. Such results
are consistent with previously published studies (e.g. Povey et
al, 2000b) showing increased MGMT activity in tumour samples:
whether this increase reﬂects differences in cell type or is due to
upregulation of gene expression or decreased exposure to alkylat-
ing agents (Povey et al, 2000a) and/or pseudosubstrates remains
to be clariﬁed.
There were no signiﬁcant differences in mean MGMT activity
distal or proximal to tumours of the rectum or sigmoid colon.
For the caecal carcinoma (patient 3) activities distal to the tumour
were higher than those proximal to the tumour (i.e. in the ileum:
P=0.03) suggesting intertissue differences in MGMT activity. Prox-
imal to all tumours the inter individual variation was *6.3-fold
whereas the intraindividual variation varied between 1.6 and
424. Distal to tumours, the inter individual variation was *6.9-
fold whereas the intraindividual variation varied between 1.1 and
2.5 (Table 2).
A consistent topographical pattern of MGMT activity in normal
mucosa associated with colorectal cancers was observed with
tumours occurring in regions of low MGMT activity. There was
a modest but signiﬁcant fall in MGMT activity, unrelated to
tumour subsite or stage, upstream of left sided tumours (Figure
1). The gradient, proximal to the tumour, ranged from 70.07 to
0.44 fmoles mg
71 DNA per cm (Table 3). The mean gradient
was 0.22 fmole mg
71 DNA per cm (95% CI=0.03–0.42: P=0.02).
Over a 10 cm length of tissue, this would correspond to between
a 10–80% drop in MGMT activity (based upon mean values
shown in Table 2). Distally, MGMT activity fell as the distance
from the tumour increased with a mean gradient of 70.17 fmoles
mg
71 DNA (95% CI=71.35–1.01) but the small distal resection
margins resulted in a limited number of assayable samples. Activity
adjacent to the caecal tumour was lowest in the ileum, and
increased with distance distal to the cancer (Figure 1: patient 3).
The gradient was 71.37 fmole mg
71 DNA proximally and
0.60 fmole mg
71 DNA distally.
The gradient in activity along the colon may reﬂect a number of
different mechanisms including longitudinal changes in gene
expression or variable exposure to alkylating agents (or pseudosub-
strates). If tumours form in areas of low MGMT activity, this
would suggest that MGMT activity is a factor predetermining
susceptibility to colorectal cancer, a hypothesis consistent with
our understanding of the known actions of MGMT in providing
protection against the mutagenic and carcinogenic effects of alky-
lating agents (O’Connor et al, 2000). If however, the tumour site
is determined by increased exposure to alkylating agents, the
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Table 2 Intra-individual variation in MGMT activity in the human large bowel
MGMT activity (fmole mg
71 DNA)
a
Proximal to tumour Distal to tumour
Patient Mean+s.d. (n) Range Variation Mean+s.d. (n) Range Variation Tumour P (ANOVA)
b
1 9.4+1.6 (8) 7.7–12.8 1.7 9.0 (2) 8.7–9.3 1.1 18.3, 13.2 0.005
2 12.3+2.8 (7) 9.2–16.1 1.8 9.7+1.5 (5) 8–12 1.5 24.9, 27.8 50.001
3 17.7+11.9 (8) 2.6–32.8 12.6 29.0+5.1 (8) 21.8–37.9 1.7 5.4, 10.2 0.012
4 12.9+2.6 (9) 9.8–16.1 1.6 14.4+1.4 (5) 12.7–15.6 1.2 27.5, 19.6 0.001
5 2.8+2.0 (15) 50.25–6.1 424.4 4.6+2.3 (3) 3.0–7.2 2.4 8.6, 7.1 0.012
6 6.9+1.6 (10) 4.2–8.4 2.0 6.3+1.8 (10) 4.0–9.8 2.5 8.0 0.52
7 4.6+0.8 (10) 3.4–5.9 1.7 4.2 (2) 3.0–5.4 1.8 13.0, 10.4 50.001
aLimit of detection *0.25 fmole mg
71 DNA.
bDifferences in MGMT activity between tumour and tissue proximal and distal to the tumour.
Table 3 Gradients of MGMT activities proximal and distal to colorectal
tumours
Gradient proximal to
tumour
a
Gradient distal to
tumour
a
Patient No of fmoles mg
71 No of fmoles mg
71
no samples DNA cm
71 samples DNA cm
71
1 8 0.16 2 70.63
2 7 0.44 5 0.33
38 71.37 8 0.60
49 70.07 5 70.35
5 15 0.34 3 2.12
6 10 0.36 10 70.48
7 10 0.07 2 72.40
aNegative gradients are associated with MGMT activity increasing as distance from
the tumour decreases.
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factor determining susceptibility. Consistent with this latter
hypothesis we have previously reported that O
6-methylguanine
levels were higher in the sigmoid colon and rectum than in the
caecum (Povey et al, 2000a). It remains to be established whether
this gradient is a reﬂection of recent exposure to alkylating agents
or perhaps low MGMT activity present earlier at the time of
tumour initiation.
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Figure 1 MGMT activity (fmoles mg
71 DNA) upstream (proximal) and downstream (distal) to colorectal tumours. The tumour is located at 0 cm:
negative and positive distances are respectively upstream (proximal) and downstream (distal) from the tumour. As two samples were taken from each
tumour, both the individual activities and the mean MGMT activity is shown.
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